| Jason David Taksey, MD | |
|
2003 Medical Pkwy, Suite 210, Annapolis, MD 21401-7992 | |
| (410) 573-5300 | |
| (410) 573-5305 |
| Full Name | Jason David Taksey |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 23 Years |
| Location | 2003 Medical Pkwy, Annapolis, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316017676 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RX0202X | Internal Medicine - Medical Oncology | D0065272 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hospice Of The Chesapeake | Pasadena, MD | Hospice |
| Anne Arundel Medical Center | Annapolis, MD | Hospital |
| University Of Md Baltimore Washington Medical Center | Glen burnie, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Maryland Oncology Hematology Pa | 2062302102 | 80 |
News Archive
Dieters and weight loss researchers are familiar with the principle: The more weight you've lost, the harder it is to keep it off. A complex and vicious cycle of biological and behavioral factors make it so.
Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology for the treatment of hypertension, announced today that it has received Conformite Europeenne (CE) Mark approval for its V2 Renal Denervation System for the treatment of hypertension.
Publication in Nature Cell Biology: researchers at the Université libre de Bruxelles, ULB define for the first time the mechanisms responsible for the mammary gland development.
Plastics contain and leach hazardous chemicals, including endocrine-disrupting chemicals (EDCs) that threaten human health.
Adaptimmune announced today that it has opened a Pilot, open-label clinical trial in synovial sarcoma at the National Cancer Institute (NCI), Bethesda, Maryland, testing its enhanced T cell receptor T cell therapy. A second site is planned to open later this year at Washington University, St. Louis, Missouri.
› Verified 5 days ago
| Entity Name | University Of Maryland Community Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477530624 PECOS PAC ID: 3678472214 Enrollment ID: O20040102000687 |
News Archive
Dieters and weight loss researchers are familiar with the principle: The more weight you've lost, the harder it is to keep it off. A complex and vicious cycle of biological and behavioral factors make it so.
Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology for the treatment of hypertension, announced today that it has received Conformite Europeenne (CE) Mark approval for its V2 Renal Denervation System for the treatment of hypertension.
Publication in Nature Cell Biology: researchers at the Université libre de Bruxelles, ULB define for the first time the mechanisms responsible for the mammary gland development.
Plastics contain and leach hazardous chemicals, including endocrine-disrupting chemicals (EDCs) that threaten human health.
Adaptimmune announced today that it has opened a Pilot, open-label clinical trial in synovial sarcoma at the National Cancer Institute (NCI), Bethesda, Maryland, testing its enhanced T cell receptor T cell therapy. A second site is planned to open later this year at Washington University, St. Louis, Missouri.
› Verified 5 days ago
| Entity Name | Maryland Oncology Hematology Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396710703 PECOS PAC ID: 2062302102 Enrollment ID: O20040319001169 |
News Archive
Dieters and weight loss researchers are familiar with the principle: The more weight you've lost, the harder it is to keep it off. A complex and vicious cycle of biological and behavioral factors make it so.
Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology for the treatment of hypertension, announced today that it has received Conformite Europeenne (CE) Mark approval for its V2 Renal Denervation System for the treatment of hypertension.
Publication in Nature Cell Biology: researchers at the Université libre de Bruxelles, ULB define for the first time the mechanisms responsible for the mammary gland development.
Plastics contain and leach hazardous chemicals, including endocrine-disrupting chemicals (EDCs) that threaten human health.
Adaptimmune announced today that it has opened a Pilot, open-label clinical trial in synovial sarcoma at the National Cancer Institute (NCI), Bethesda, Maryland, testing its enhanced T cell receptor T cell therapy. A second site is planned to open later this year at Washington University, St. Louis, Missouri.
› Verified 5 days ago
| Entity Name | Luminis Health Medical Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073580205 PECOS PAC ID: 2860447315 Enrollment ID: O20050317000146 |
News Archive
Dieters and weight loss researchers are familiar with the principle: The more weight you've lost, the harder it is to keep it off. A complex and vicious cycle of biological and behavioral factors make it so.
Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology for the treatment of hypertension, announced today that it has received Conformite Europeenne (CE) Mark approval for its V2 Renal Denervation System for the treatment of hypertension.
Publication in Nature Cell Biology: researchers at the Université libre de Bruxelles, ULB define for the first time the mechanisms responsible for the mammary gland development.
Plastics contain and leach hazardous chemicals, including endocrine-disrupting chemicals (EDCs) that threaten human health.
Adaptimmune announced today that it has opened a Pilot, open-label clinical trial in synovial sarcoma at the National Cancer Institute (NCI), Bethesda, Maryland, testing its enhanced T cell receptor T cell therapy. A second site is planned to open later this year at Washington University, St. Louis, Missouri.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jason David Taksey, MD Po Box 12622, Belfast, ME 04915-4017 Ph: (443) 481-6571 | Jason David Taksey, MD 2003 Medical Pkwy, Suite 210, Annapolis, MD 21401-7992 Ph: (410) 573-5300 |
News Archive
Dieters and weight loss researchers are familiar with the principle: The more weight you've lost, the harder it is to keep it off. A complex and vicious cycle of biological and behavioral factors make it so.
Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology for the treatment of hypertension, announced today that it has received Conformite Europeenne (CE) Mark approval for its V2 Renal Denervation System for the treatment of hypertension.
Publication in Nature Cell Biology: researchers at the Université libre de Bruxelles, ULB define for the first time the mechanisms responsible for the mammary gland development.
Plastics contain and leach hazardous chemicals, including endocrine-disrupting chemicals (EDCs) that threaten human health.
Adaptimmune announced today that it has opened a Pilot, open-label clinical trial in synovial sarcoma at the National Cancer Institute (NCI), Bethesda, Maryland, testing its enhanced T cell receptor T cell therapy. A second site is planned to open later this year at Washington University, St. Louis, Missouri.
› Verified 5 days ago
Gashaw Adugna Dadi, M.D Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2001 Medical Pkwy, Annapolis, MD 21401 Phone: 240-495-4189 | |
Dr. Eugene Thomas Manion, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 900 Bestgate Road, Suite 303, Annapolis, MD 21401 Phone: 410-224-8220 Fax: 410-841-2482 | |
Dr. Lisa A Dimarzio, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 2003 Medical Parkway, Suite 100, Annapolis, MD 21401 Phone: 410-573-1110 Fax: 410-266-0714 | |
Dr. Richard A Bernstein, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 133 Defense Hwy, Suite 109, Annapolis, MD 21401 Phone: 401-224-5558 Fax: 410-224-7321 | |
Dr. Jonathan A Altschuler, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2002 Medical Pkwy, Ste 500, Annapolis, MD 21401 Phone: 410-573-6480 Fax: 410-573-9413 | |
Dr. Ira M Weinstein, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2000 Medical Pkwy, Suite 607, Annapolis, MD 21401 Phone: 410-266-1644 Fax: 410-266-1642 | |
Dr. James M Blake, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 820 Bestgate Road, Suite 2a, Annapolis, MD 21401 Phone: 410-224-2116 Fax: 410-224-2118 |